Eli Lilly and Company (LLY) Shares Bought by Darrell & King LLC
Darrell & King LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 46.3% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,477 shares of the company’s stock after acquiring an additional 2,050 shares during the quarter. Darrell & King LLC’s holdings in Eli Lilly and were worth $533,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Hartland & Co. LLC increased its stake in Eli Lilly and by 3.9% in the 2nd quarter. Hartland & Co. LLC now owns 10,787 shares of the company’s stock worth $888,000 after acquiring an additional 401 shares during the last quarter. Highstreet Asset Management Inc. bought a new position in Eli Lilly and in the 2nd quarter worth about $814,000. BARING ASSET MANAGEMENT Ltd bought a new position in Eli Lilly and in the 2nd quarter worth about $1,668,000. Legal & General Group Plc increased its stake in Eli Lilly and by 2.8% in the 2nd quarter. Legal & General Group Plc now owns 5,101,196 shares of the company’s stock worth $419,840,000 after acquiring an additional 136,660 shares during the last quarter. Finally, Alps Advisors Inc. increased its stake in Eli Lilly and by 3.4% in the 2nd quarter. Alps Advisors Inc. now owns 578,098 shares of the company’s stock worth $47,577,000 after acquiring an additional 19,110 shares during the last quarter. Institutional investors and hedge funds own 75.72% of the company’s stock.
LLY has been the topic of a number of research analyst reports. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Berenberg Bank reiterated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a report on Thursday, July 27th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a report on Monday, July 17th. Deutsche Bank AG reiterated a “buy” rating and issued a $91.00 price objective (up from $90.00) on shares of Eli Lilly and in a report on Monday, July 17th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $96.00 price objective (up from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $88.57.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the previous year, the business earned $0.86 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 990,000 shares of company stock valued at $82,949,650 in the last 90 days. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.